Researchers used electronic health records to track 190 diagnostic errors made during primary care visits at one of two healthcare facilities.

FORBES: Study: Missed Diagnoses in the Doctor's Office are Leading to Thousands of Deaths

Myriad Genetics (MYGN), a leading developer of molecular diagnostic and therapeutic products, is predictably on track to expand its pipeline and broaden its markets in the U.S. and overseas.

FORBES: Myriad Genetics: This Leading Developer of Diagnostic Products Is Catching The Eye Of Potential Big Pharma Partners